Trivitron Healthcare's Role in Advancing Newborn Screening for G6PD Deficiency Worldwide

 

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic disorder affecting red blood cells, caused by mutations in the G6PD gene. Newborn metabolic screening for G6PD deficiency is crucial in identifying babies at risk of severe jaundice, hemolytic anemia, and other complications related to the disorder. Universal newborn screening for G6PD deficiency is a routine part of national health programs in countries where it is prevalent. However, it is not widely available in other countries, and many affected babies may not be diagnosed until they develop symptoms.

Trivitron Healthcare is a leading manufacturer and supplier of neonatal G6PD screening assays, including their highly sensitive and specific Neonatal G6PD assay. The assay uses a fluorometric method to measure the activity of the G6PD enzyme in red blood cells, with minimal training required, and is compatible with most clinical chemistry analyzers, making it convenient for laboratories to incorporate into their routine testing protocols.

Early identification of G6PD deficiency allows healthcare providers to closely monitor affected newborns and provide prompt treatment if necessary, reducing the risk of severe jaundice, hemolytic anemia, and other complications. Trivitron Healthcare's commitment to improving newborn screening for G6PD deficiency is part of their broader mission to enhance the quality of healthcare worldwide, with their innovative products and solutions used in hospitals and laboratories in over 165 countries. Trivitron Healthcare's Neonatal G6PD assay is a reliable and accurate newborn screening kit, contributing to preventing the serious complications associated with G6PD deficiency.